Apimeds Pharmaceuticals US, Inc.Apimeds Pharmaceuticals US, Inc.Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc.

No trades
See on Supercharts

APUS fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Hopewell, NJ.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
APUS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company